NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

NRx Pharmaceuticals, Inc. (NRXP) Stock Analysis

NRx Pharmaceuticals, Inc. (NRXP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NRXP

$2.63

+$0.01 (+0.38%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NRXP with… →

NRXP Key Statistics

As of Oct 21, 2026
Trading
Open
$2.65
Previous Close
$2.62
Day's Range
2.62–2.70
52-Week Range
1.62–5.06
Volume
526.49K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.07
Valuation
Market Cap
$113.87M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
33.55
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.58
Financials (FY)
Revenue (FY)
$1.23M
Net Income (FY)
−$28.62M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
43.30M
1-Year Return
−18.07%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
878.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NRXP closed at $2.63, −18.07% over 1 year.

NRx Pharmaceuticals, Inc. (NRXP) has a market capitalization of $113.87M.

In fiscal 2025, NRXP reported revenue of $1.23M.

NRXP Stock Return by Calendar Year

NRx Pharmaceuticals, Inc. (NRXP) return since Dec 2017: what $10,000 became

1 year
$10,000 $8,193
−18.07%
5 years
$10,000 $247
−97.53%
Since Dec 2017
$10,000 $274
−97.26%

If you had invested $10,000 in NRx Pharmaceuticals, Inc. (NRXP) at the close on December 4, 2017, the earliest close on record here, it would have been worth $274 at the close on October 21, 2026: −97.26% in total, −33.31% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.95%
2025+23.18%
2024−52.17%
2023−58.56%
2022−76.78%
2021−80.41%
2020+130.19%
2019+3.92%
2018+5.37%
2017 (partial year)+0.83%

As of October 21, 2026.

NRXP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.23M−$28.62M−2,336.5%
2024$0.00−$25.13M—
2023$0.00−$30.15M—
2022$0.00−$39.75M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.23M$720.00K−$16.22M−$28.62M−2,336.5%
2024$0.00$0.00−$18.50M−$25.13M—
2023$0.00—−$27.59M−$30.15M—
2022$0.00—−$44.34M−$39.75M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NRXP Valuation vs Biotechnology Median

Median of 608 stocks
MetricNRXPBiotechnology medianvs median
P/S ratio33.5513.30152% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NRx Pharmaceuticals, Inc. (NRXP) is capitalised at $113.87M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 29 employees.

The 52-week range on file runs from $1.62 to $5.06. The most recent close on file for NRXP is $2.63, dated October 21, 2026. That is +$0.01 (+0.38%) against the previous close. The latest close sits 62.35% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.23M. The same year closed with a net loss of $28.62M. Trailing earnings per share are −0.58.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $1.23M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 33.55. On price-to-sales that is 152.28% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −18.07%. Measured over 5 years, that is −52.29% a year compounded. The reported beta is 2.07. Daily returns over the trailing 8 years annualize to a volatility of 118.97%.

Growth & Income

No dividend is on file for NRXP.

Across the complete calendar years on file, 2020 returned +130.19% and 2021 returned −80.41%. Of the 8 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is −2.95% year to date.

Peer Comparison

NRx Pharmaceuticals, Inc. (NRXP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NRx Pharmaceuticals, Inc. NRXP $113.87M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. NRx Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Visit website →